Hyperactive Ras Signaling in Developmental Disorders and Childhood Cancer-Abelson Hematology Lecture
Objectives and Disclosures
Participants will be able to:
- Analyze the role of Ras/MAP kinase pathway mutations in developmental disorders and juvenile myelomonocytic leukemia.
- Outline how genetically engineered mouse models of pediatric developmental disorders and leukemia can be used to test new therapies.
- Analyze the practical, ethical, and scientific differences between treating patients with cancer and developmental disorders caused by Ras pathway mutations.
Seattle Children’s CME Planners and today’s speaker disclose they have no relevant financial relationships.
Speaker(s)
Kevin Shannon, MDDistinguished Professor, Pediatric Molecular Oncology, Professor, Pediatrics, University of California at San Francisco
Date
7.25.24CME Credit
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this online educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.